Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices 67755 

absorbed and tolerated, with a half-life 

of approximately 12 hours (3). Adverse 

effects most associated with 

doxycycline are photosensitivity and 

gastrointestinal symptoms including 

esophageal erosion and ulceration (4). 

Most adverse effects resolve when the 

medication is stopped. Doxycycline is 

the recommended treatment regimen for 

chlamydia and an alternative treatment 

for syphilis in non-pregnant patients 

with severe penicillin allergy or when 

penicillin is not available (5). 

The 2021 CDC STI Treatment 

Guidelines included a systematic review 

of the available literature on STI PEP 

and concluded that further studies were 

necessary to determine whether it 

would be an effective strategy for 

bacterial STI prevention (5). Since that 

time, promising results from several 

randomized trials on doxycycline PEP 

indicated the need to re-address this 

topic (6, 7). The new guidelines will 

offer an important resource for 

healthcare providers to inform the use 

of doxycycline PEP for preventing 

bacterial STI infections. CDC plans to 

use multiple surveillance systems to 

monitor impacts of the proposed 

guidelines including potential impacts 

on antibiotic use and antibiotic 

resistance in both STI and non-STI 

pathogens. 

All comments received will be 

carefully reviewed and considered. The 

proposed guidelines are also undergoing 

peer review. All comments will be 

addressed in the final guidelines and 

the proposed guidelines will be revised 

as appropriate. CDC will publish 

another notice announcing the 

availability of the final guidelines. 

References 

1. STI National Strategic Plan, 2021–2025 

[internet]. Available from: www.hhs.gov/ 

programs/topic-sites/sexuallytransmitted-infections/plan-overview/ 

index.html. 

2. Nadelman RB, Nowakowski J, Fish D, 

Falco RC, Freeman K, McKenna D, et al. 

Prophylaxis with single-dose 

doxycycline for the prevention of Lyme 

disease after an Ixodes scapularis tick 

bite. N Engl J Med. 2001 Jul 

12;345(2):79–84. 

3. Peyriere H, Makinson A, Marchandin H, 

Reynes J. Doxycycline in the 

management of sexually transmitted 

infections. J Antimicrob Chemother. 

2018 Mar 1;73(3):553–63. 

4. Sloan B, Scheinfeld N. The use and safety 

of doxycycline hyclate and other secondgeneration tetracyclines. Expert Opin 

Drug Saf. 2008 Sep;7(5):571–7. 

5. Workowski K, Bachmann L, Chan P, 

Johnston C, Muzny C, Park I, et al. 

Sexually Transmitted Infections 

Treatment Guidelines, 2021. MMWR. 

2021; 70:1–187. 

6. Luetkemeyer AF, Donnell D, Dombrowski 

JC, Cohen S, Grabow C, Brown CE, et al. 

Postexposure Doxycycline to Prevent 

Bacterial Sexually Transmitted 

Infections. N Engl J Med. 2023 Apr 

6;388(14):1296–306. 

7. Jean-Michel Molina, Beatrice Bercot, 

Lambert Assoumou, Algarte-Genin 

Michele, Emma Rubenstein, Gilles 

Pialoux, et al. ANRS 174 DOXYVAC: An 

Open-Label Randomized Trial to Prevent 

STIs in MSM on PrEP. CROI [internet]. 

2023 Feb 19; Seattle, Washington. 

Available from: https://

www.croiconference.org/abstract/anrs174-doxyvac-an-open-label-randomizedtrial-to-prevent-stis-in-msm-on-prep/. 

Dated: September 27, 2023. 

Kathryn L. Wolff, 

Chief of Staff, Centers for Disease Control 

and Prevention. 

[FR Doc. 2023–21725 Filed 9–29–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–R–26, CMS–R– 

185, CMS–116, CMS–2746 and CMS–10261] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

ACTION: Notice; partial withdrawal. 

SUMMARY: On Monday, September 25, 

2023, the Centers for Medicare & 

Medicaid Services (CMS) published a 

notice document entitled, ‘‘Agency 

Information Collection Activities: 

Submission for OMB Review; Comment 

Request.’’ That notice invited public 

comments on five separate information 

collection requests, under Document 

Identifiers: CMS–R–26, CMS–R– 185, 

CMS–116, CMS–2746 and CMS–10261. 

Through the publication of this 

document, we are withdrawing the 

portion of the notice requesting public 

comment on the information collection 

request titled, ‘‘Clinical Laboratory 

Improvement Amendments (CLIA) 

Regulations.’’ Form number: CMS–R–26 

(OMB control number: 0938–0612). We 

are also withdrawing the portion of the 

notice requesting public comment on 

the information collection request titled, 

‘‘Granting and Withdrawal of Deeming 

Authority to Private Nonprofit 

Accreditation Organizations and CLIA 

Exemption Under State Laboratory 

Programs.’’ Form number: CMS–R–185 

(OMB control number 0938–0686). 

DATES: The original comment period for 

the document that published on 

September 25, 2023, remains in effect 

and ends October 25, 2023. 

SUPPLEMENTARY INFORMATION: 

In FR document, 2023–20739, 

published on September 25, 2023 (88 FR 

65689), we are withdrawing item 1 ’’ 

Clinical Laboratory Improvement 

Amendments (CLIA) Regulations’’ 

which begins on page 65689. We are 

also withdrawing item 2 ’’ Granting and 

Withdrawal of Deeming Authority to 

Private Nonprofit Accreditation 

Organizations and CLIA Exemption 

Under State Laboratory Programs.’’ 

which begin on page 65690. These items 

were published in error. Both items will 

be republished at a later date, thereby 

providing the public a full 30-day 

comment period as required by the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 3501 et seq.). 

Dated: September 27, 2023. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2023–21669 Filed 9–29–23; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3443–FN] 

Medicare and Medicaid Programs; 

Application From the Center for 

Improvement in Healthcare Quality for 

Initial CMS Approval of Its Psychiatric 

Hospital 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces our 

decision to approve the Center for 

Improvement in Healthcare Quality 

(CIHQ) as a national accrediting 

organization (AO) for psychiatric 

hospitals that wish to participate in the 

Medicare or Medicaid programs. 

DATES: The decision announced in this 

notice is applicable on November 1, 

2023 through November 1, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Donald Howard, (410) 786–6764 or 

Lillian Williams, (410) 786–8636. 

SUPPLEMENTARY INFORMATION: 

I. Background 

Under the Medicare program, eligible 

beneficiaries may receive covered 

services from a psychiatric hospital 


lotter on DSK11XQN23PROD with NOTICES1